Treatment with the MMP2 inhibitor resulted in reduced migration in each of the RCC cell lines (Fig. 4G), demonstrating that MMP2 activity does contribute to the Ror2 invasive phenotype. This evidence concerns the gene ROR2 and renal cell carcinoma.